03.01.2017 • NewsElaine BurridgeMerck & Co.Pharmaceutical

India’s Zydus Buys Brands from US Merck

(c) AJP/Shutterstock
(c) AJP/Shutterstock

Indian pharmaceutical company Zydus Cadila has acquired six brands from US drugmaker Merck for an undisclosed sum. The branded products are anabolic steroids Deca-Durabolin and Durabolin, which are widely prescribed for treating osteoporosis, injectable testosterone Sustanon, intra-uterine device Multiload, hypertension treatment Sicastat and Axeten used in wound management.

The deal includes the transfer of distribution and commercialization rights as well as assignment of all the trademarks to wholly owned subsidiary Zydus Healthcare.

As part of the transaction, Organon (India) Private, a Merck subsidiary operating in the country, has also transferred distribution and commercialization rights for Deca-Durabolin and Durabolin in Nepal.

Chairman of Zydus Healthcare, Sharvil Patel, said the Ahmedabad-based company has a longstanding association with Merck in India, and the acquisition of the complementary brands provides a great opportunity to strengthen its core offerings to create value and growth. The acquired portfolio had sales of 840 million Rupees – around $12 million – in 2015, and Zydus said it expects to grow the brands significantly during the next few years.

With revenues of more than Rs 9,800 crore ($1.4 billion) in 2016, the Indian group is aiming to become a research-based pharmaceutical firm by 2020. Zydus Cadila also operates in Europe (France and Spain), the US, Latin America and South Africa.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.